encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer
Published 3 years ago • 386 plays • Length 8:16
Download video MP4
Download video MP3
Similar videos
-
1:45
breakwater: encorafenib plus cetuximab in patients with braf v600e-mutant mcrc
-
5:04
beacon: encorafenib plus cetuximab with or without binimetinib for braf v600e–mutant metastatic ...
-
6:23
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
1:13
dr. lenz on breakthrough designation of encorafenib, binimetinib, and cetuximab in braf crc
-
1:15
big bang: binimetinib, encorafenib, and cetuximab in braf non-v600e mutated mcrc
-
17:01
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
0:56
dr. bekaii-saab on tolerability of encorafenib, binimetinib, and cetuximab in braf crc
-
1:17
treatment approaches for braf v600e mutant metastatic colorectal cancer
-
3:25
first-line triplet in braf mcrc
-
13:48
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
0:54
triplet therapy for certain patients with metastatic crc shows promise, but more research is needed
-
1:20
jeffrey a. meyerhardt, md, considers the beacon study in braf mutated metastatic colorectal cancer
-
2:08
fda approves encorafenib binimetinib for metastatic nsclc with a braf v600e mutation
-
13:13
encorafenib, binimetinib, and cetuximab in braf v600e–mutated colorectal cancer
-
4:25
fire-4.5: folfoxiri plus either bevacizumab or cetuximab in mcrc
-
2:07
triplet regimen improves responses in braf v600e metastatic crc
-
9:28
new therapy options for braf-mutated mcrc
-
1:18
safety lead-in data for beacon crc trial with triplet biologic regimen in mcrc
-
4:51
colorectal cancer debate: first line braf v600e - folfoxiri/bev
Clip.africa.com - Privacy-policy